PDF(Pubmed)
Abstract：
Pulmonary embolism, while a rare and life-threatening condition, is increasingly recognized in the context of pregnancy, particularly when compounded by infections such as coronavirus disease 2019 (COVID-19). This case report describes a 34-year-old pregnant woman, at 32 weeks of gestation, who developed COVID-19-related coagulopathy despite prophylactic treatment with low molecular weight heparin (LMWH). Admitted with symptoms of breathlessness, fever, and cough, she was diagnosed with COVID-19 and subsequently developed pulmonary embolism. This development was particularly unusual given her ongoing LMWH therapy. Diagnosis in such cases relies heavily on clinical assessment, evaluation of risk factors, and diagnostic tools, with computed tomography pulmonary angiography being pivotal for confirmation. This case highlights the complexities involved in managing COVID-19 among pregnant patients, especially the increased risk and diagnostic challenges associated with thromboembolic disorders. The successful resolution of the case, attributed to a multidisciplinary team\'s timely intervention and coordinated approach, emphasizes the critical need for prompt and individualized treatment strategies in similar clinical scenarios.
摘要：
肺栓塞,虽然是一种罕见的危及生命的疾病，在怀孕的背景下越来越得到认可，特别是当感染如2019年冠状病毒病（COVID-19）时。这个病例报告描述了一个34岁的孕妇,妊娠32周时，尽管使用低分子量肝素（LMWH）进行了预防性治疗，但仍出现了COVID-19相关的凝血病。出现呼吸困难症状，发烧,咳嗽,她被诊断为COVID-19,随后出现肺栓塞.鉴于她正在进行的LMWH治疗，这种发展尤其不寻常。这种情况下的诊断很大程度上依赖于临床评估，风险因素评估，和诊断工具，计算机断层扫描肺动脉造影是确认的关键。这一案例凸显了在怀孕患者中管理COVID-19所涉及的复杂性，尤其是与血栓栓塞性疾病相关的风险增加和诊断挑战。案件的成功解决，归因于多学科团队的及时干预和协调方法，强调在类似的临床情况下，迫切需要及时和个性化的治疗策略。
